DFO
NAMS icon

Duquesne Family Office’s NewAmsterdam Pharma NAMS Stock Holding History

Duquesne Family Office’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.3M Hold
3,070,146
– – 3.35% 10
2025
Q4 		$108M Buy
3,070,146
+1,146,446
+60% +$41.7M 2.55% 14
2025
Q3 		$54.7M Buy
1,923,700
+1,091,525
+131% +$26.2M 1.39% 19
2025
Q2 		$15.1M Buy
832,175
+31,815
+4% +$580K 0.39% 53
2025
Q1 		$16.4M Buy
800,360
+512,825
+178% +$11.4M 0.55% 38
2024
Q4 		$7.39M Hold
287,535
– – 0.21% 63
2024
Q3 		$4.77M Buy
+287,535
New +$4.97M 0.17% 65

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return